Astrocytic GABA Transporters: Pharmacological Properties and Targets for Antiepileptic Drugs

Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Communication

Standard

Astrocytic GABA Transporters : Pharmacological Properties and Targets for Antiepileptic Drugs. / Schousboe, Arne; Wellendorph, Petrine; Frølund, Bente; Clausen, Rasmus P; Krogsgaard-Larsen, Povl.

Glial Amino Acid Transporters. Vol. 16 Springer, 2017. p. 283-296 (Advances in Neurobiology).

Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Communication

Harvard

Schousboe, A, Wellendorph, P, Frølund, B, Clausen, RP & Krogsgaard-Larsen, P 2017, Astrocytic GABA Transporters: Pharmacological Properties and Targets for Antiepileptic Drugs. in Glial Amino Acid Transporters. vol. 16, Springer, Advances in Neurobiology, pp. 283-296. https://doi.org/10.1007/978-3-319-55769-4_14

APA

Schousboe, A., Wellendorph, P., Frølund, B., Clausen, R. P., & Krogsgaard-Larsen, P. (2017). Astrocytic GABA Transporters: Pharmacological Properties and Targets for Antiepileptic Drugs. In Glial Amino Acid Transporters (Vol. 16, pp. 283-296). Springer. Advances in Neurobiology https://doi.org/10.1007/978-3-319-55769-4_14

Vancouver

Schousboe A, Wellendorph P, Frølund B, Clausen RP, Krogsgaard-Larsen P. Astrocytic GABA Transporters: Pharmacological Properties and Targets for Antiepileptic Drugs. In Glial Amino Acid Transporters. Vol. 16. Springer. 2017. p. 283-296. (Advances in Neurobiology). https://doi.org/10.1007/978-3-319-55769-4_14

Author

Schousboe, Arne ; Wellendorph, Petrine ; Frølund, Bente ; Clausen, Rasmus P ; Krogsgaard-Larsen, Povl. / Astrocytic GABA Transporters : Pharmacological Properties and Targets for Antiepileptic Drugs. Glial Amino Acid Transporters. Vol. 16 Springer, 2017. pp. 283-296 (Advances in Neurobiology).

Bibtex

@inbook{e42ca3d520e34b11b634247f8bea4242,
title = "Astrocytic GABA Transporters: Pharmacological Properties and Targets for Antiepileptic Drugs",
abstract = "Inactivation of GABA-mediated neurotransmission is achieved by high-affinity transporters located at both GABAergic neurons and the surrounding astrocytes. Early studies of the pharmacological properties of neuronal and glial GABA transporters suggested that different types of transporters might be expressed in the two cell types, and such a scenario was confirmed by the cloning of four distinctly different GABA transporters from a number of different species. These GABA-transport entities have been extensively characterized using a large number of GABA analogues of restricted conformation, and several of these compounds have been shown to exhibit pronounced anticonvulsant activity in a variety of animal seizure models. As proof of concept of the validity of this drug development approach, one GABA-transport inhibitor, tiagabine, has been developed as a clinically active antiepileptic drug. This review provides a detailed account of efforts to design new subtype-selective GABA-transport inhibitors aiming at identifying novel antiepileptic drug candidates.",
keywords = "Journal Article",
author = "Arne Schousboe and Petrine Wellendorph and Bente Fr{\o}lund and Clausen, {Rasmus P} and Povl Krogsgaard-Larsen",
year = "2017",
doi = "10.1007/978-3-319-55769-4_14",
language = "English",
volume = "16",
series = "Advances in Neurobiology",
publisher = "Springer",
pages = "283--296",
booktitle = "Glial Amino Acid Transporters",
address = "Switzerland",

}

RIS

TY - CHAP

T1 - Astrocytic GABA Transporters

T2 - Pharmacological Properties and Targets for Antiepileptic Drugs

AU - Schousboe, Arne

AU - Wellendorph, Petrine

AU - Frølund, Bente

AU - Clausen, Rasmus P

AU - Krogsgaard-Larsen, Povl

PY - 2017

Y1 - 2017

N2 - Inactivation of GABA-mediated neurotransmission is achieved by high-affinity transporters located at both GABAergic neurons and the surrounding astrocytes. Early studies of the pharmacological properties of neuronal and glial GABA transporters suggested that different types of transporters might be expressed in the two cell types, and such a scenario was confirmed by the cloning of four distinctly different GABA transporters from a number of different species. These GABA-transport entities have been extensively characterized using a large number of GABA analogues of restricted conformation, and several of these compounds have been shown to exhibit pronounced anticonvulsant activity in a variety of animal seizure models. As proof of concept of the validity of this drug development approach, one GABA-transport inhibitor, tiagabine, has been developed as a clinically active antiepileptic drug. This review provides a detailed account of efforts to design new subtype-selective GABA-transport inhibitors aiming at identifying novel antiepileptic drug candidates.

AB - Inactivation of GABA-mediated neurotransmission is achieved by high-affinity transporters located at both GABAergic neurons and the surrounding astrocytes. Early studies of the pharmacological properties of neuronal and glial GABA transporters suggested that different types of transporters might be expressed in the two cell types, and such a scenario was confirmed by the cloning of four distinctly different GABA transporters from a number of different species. These GABA-transport entities have been extensively characterized using a large number of GABA analogues of restricted conformation, and several of these compounds have been shown to exhibit pronounced anticonvulsant activity in a variety of animal seizure models. As proof of concept of the validity of this drug development approach, one GABA-transport inhibitor, tiagabine, has been developed as a clinically active antiepileptic drug. This review provides a detailed account of efforts to design new subtype-selective GABA-transport inhibitors aiming at identifying novel antiepileptic drug candidates.

KW - Journal Article

U2 - 10.1007/978-3-319-55769-4_14

DO - 10.1007/978-3-319-55769-4_14

M3 - Book chapter

C2 - 28828616

VL - 16

T3 - Advances in Neurobiology

SP - 283

EP - 296

BT - Glial Amino Acid Transporters

PB - Springer

ER -

ID: 194772856